The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...

Today researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from the first ever clinical trial to show ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.